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Available online 29 September 2016Introduction: Recently, novel calreticulin (CALR)mutationswere discovered in Janus kinase 2 (JAK2) non-mutat-
ed myeloﬁbrosis (PMF) and essential thrombocythemia (ET) cases, with a frequency of 60–80%. We examined
clinical correlations and CALR mutation frequency in our myeloproliferative neoplasms (MPN) cases, and intro-
duce an effective test method for use in clinical practice.
Methods:We examined 177 samples previously investigated for the JAK2 mutation for differential diagnosis of
MPN. JAK2 and CALR mutations were analyzed using melting curve analysis and microchip electrophoresis, re-
spectively. Next, we constructed a test for simultaneous screening of the JAK2 and CALR mutations utilizing
high resolution melting (HRM).
Results: Among 99MPN cases, 60 possessed the JAK2mutation alone. Of the 39MPN caseswithout the JAK2mu-
tation, 14 were positive for the CALR mutation, all of which were ET. Using our novel screening test for the JAK2
and CALRmutations by HRM, the concordance rate of conventional analysis with HRMwas 96% for the JAK2mu-
tation and 95% for the CALR mutation.
Conclusion: Our novel simultaneous screening test for the JAK2 and CALR gene mutations with HRM is useful for
diagnosis of MPN.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Screening test1. Introduction
Myeloproliferative neoplasms (MPN) are a group of chronicmyeloid
cancer diseases characterized by overproduction of mature blood
cells [1,2]. Except for chronic myelogenous leukemia (CML), the 3
most common types of MPN are polycythemia vera (PV), essential
thrombocythemia (ET), and primary myeloﬁbrosis (PMF). In many
cases, these diseases develop slowly and gradually worsen, whileproliferative neoplasms; (PV),
(PMF), Primary myeloﬁbrosis;
(CML), chronic myelogenous
(PLT), platelet; (MCV), mean
, lactate dehydrogenase; (IL-3),
ivator of transcription; (MDS),
ukemia.
Medicine, Nagasaki University
).
. This is an open access article undersome can progress to leukemia. Many patients with BCR-ABL-negative
MPN carry the Janus kinase 2 V617F (JAK2) mutation [3,4]. Either that
or JAK2 exon 12 mutation are found in most patients with PV, whereas
one of those is found in only 50–60% of patients with ET or PMF [5–7]. In
addition, mutations in the thrombopoietin receptor gene (myeloprolif-
erative leukemia, MPL) have been reported in patients with JAK2muta-
tion-negative MPN. MPL mutational frequencies are estimated at 3% in
ET and 10% in PMF [8]. Tests for the JAK2mutation have greatly simpli-
ﬁed diagnosis of MPN and are now ﬁrmly established as front-line
examinations [9]. However, distinguishing ET cases possessing non-
mutated JAK2 from the much more common reactive thrombocytosis
remains a major diagnostic problem.
In December 2013, two groups reported novel calreticulin (CALR)
mutations (exon 9 deletions and insertions) in ET and PMF patients
possessing non-mutated JAK2 or MPL [10,11]. In the ﬁrst of those stud-
ies [10], they examined 1107 samples from patients with MPN and
noted that CALR mutations were not seen in any with PV (n = 382),
whereas they were detected in patients with ET (n = 311) or PMF
(n = 203). Interestingly, the occurrence of CALR mutations wasthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1.Mutation analysis of JAK2 by melting curve analysis and the CALR gene by microchip electrophoresis. (a–c) Representative results of melting curve analysis for JAK2. Green line:
positive control. Black line: negative control. Red line: representative samples. (a) wild-type JAK2 (b) heterozygous JAK2 mutation (c) homozygous JAK2 mutation. (d–f)
Representative results of PCR for the CALR gene. (d) A single 386-bp band (arrow) was observed in specimens with the wild-type CALR gene. (e) A band smaller than that seen with
the wild type was observed in the 52-bp deletion type. (f) An additional band was detected in the 5-bp insertion type.
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ingly, the authors examined 211 additional JAK2/MPL-non-mutated
cases and found that the CALR mutational frequency in JAK2/MPL-neg-
ative disease was 67% in ET and 88% in PMF. In consideration of the
promising results presented in recent reports, diagnostic criteria used
for MPNmay be revised in the near future. In the present study, we ex-
amined the frequency and clinical correlations of the JAK2 and CALR
mutations in MPN patients treated at our institution, and introduce
our novel screening testing method utilizing high resolution melting
(HRM) for use in clinical practice.Table 1
Frequencies of JAK2 and CALR gene mutations in 177 cases.
Clinical diagnosis
No. of
samples
JAK2 mutation CALR mutation
Occurrence
Frequency
(%) Occurrence
Frequency
(%)
MPN 99
ET 43 24 56 14 43
PV 38 32 84 0 0
PMF 7 4 57 0 0
CML 11 0 0 0 0
Secondary or stress
polycythemia
15 0 0 0 0
Reactive
thrombocytosis
8 0 0 0 0
MDS 5 0 0 0 0
AML 3 0 0 0 0
Others 47 0 0 0 02. Materials and methods
2.1. Sample preparation
We examined samples from 177 patients previously investigated for
the presence of the JAK2 mutation for differential diagnosis of MPN in
patients treated at Nagasaki University Hospital, between 2008 and
2014. The ﬁnal clinical diagnosis was PV in 38 cases, ET in 43, PMF in
7, secondary or stress polycythemia in 15, reactive thrombocytosis in
8, CML in 11, MDS in 5, AML in 3, and others in 47. Diagnosis of PMN
or other diseases was performed at the time of the ﬁrst observation in
accordance with the WHO criteria presented in 2008.
This retrospective study received approval from the Ethics Commit-
tee of Nagasaki University Hospital (No. 16042540), and all procedures
used were in accordance with the Helsinki Declaration, revised in 2000.
2.2. Detection of JAK2 V617F mutation using melting curve analysis
DNA was extracted from bone marrow samples or peripheral blood
using QuickGene-800 (FUJIFILM, Japan). Codon 12 of the JAK2 gene was
ampliﬁed using the LightCycler platform (Roche, Basel, Switzerland).
Real-time PCR was performed using each specimen with 5 μL of puriﬁed
DNA extract in a total reaction volume of 20 μL that included 2 μL of
FastStart DNA Master Hybri Probe 10× reaction master mix (Roche)
under the following conditions: forward primer, 5′-AAGCAGCAAGT
ATGATGAGCAA-3′ (ﬁnal concentration 0.5 μM); reverse primer 5′-
AGCTGTGATCCTGAAACTGAA-3′ (ﬁnal concentration 0.5 μM); FITC
probe 5-GTAGTTTTACTTACTCTCGTCTC-FITC-3 (ﬁnal concentration
WBC Hb(× 109/L) (g/L)
JAK2 mutation(+) CALR mutation(+) JAK2 mutation(-)CALR mutation(-)
(a) (b)
PLT LDH( 109/L) (IU/L)
*
JAK2 mutation(+) CALR mutation(+) JAK2 mutation(-)CALR mutation(-)
(c) (d)
×
Fig. 2. Comparison of laboratory ﬁndings among ET cases possessing the CALRmutation, JAK2mutation, or nomutation. (a, b, e) There were no signiﬁcant differences amongWBC count,
Hb level, andMCV. (c) PLT count in cases possessing the CALRmutation was signiﬁcantly higher as compared to the JAK2mutation-positive cases. (d, f) LD level showed a tendency to be
higher and MPV a tendency to be lower in cases possessing the CALR mutation as compared to the JAK2 mutation-positive cases. ⁎P values b 0.05 were regarded to indicate statistical
signiﬁcance.
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concentration 0.2 μM), and nuclease-free water. The PCR cycle parame-
ters were an initial denaturing step at 95 °C for 10 min and 40 cycles
consisting of 95 °C for 10 s, 60 °C for 10 s, and 75 °C for 15 s. DNAmelting
curve analysis was performed by denaturing at 95 °C for 0 s, annealing at
35 °C for 10 s, and melting with a transition rate of 0.20 °C/s to 80 °C.
Either wild-type or homozygous mutation was deﬁned by the presence
of one temperature peak and a heterozygous mutation was deﬁned by
the presence of two temperature peaks.2.3. Detection of CALR gene mutation by microchip electrophoresis and
direct sequencing
DNAwas extracted from the samples and ampliﬁed by PCR using the
following primers: forward, 5′-ACAACTTCCTCATCACCAACG-3′; reverse,
5′- GGCCTCAGTCCAGCCCTG-3′. Each PCR reactionwas performed using
AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster City, CA)
under the following conditions: 35 total cycles of denaturation at
94 °C for 20 s, annealing at 60 °C for 30 s, and extension at 72 °C for
MCV MPV
(f l) (f l)
JAK2 mutation(+) CALR mutation(+) JAK2 mutation(-)CALR mutation(-)
(e) (f)
Fig. 2 (continued).
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chip electrophoresis systemMCE-202 (Shimadzu, Kyoto, Japan) accord-
ing to the manufacturer's instructions. To conﬁrm the positivity of a
CALR mutation, direct sequencing was performed in both directions
using an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems) ac-
cording to the manufacturer's instructions.2.4. Simultaneous screening for JAK2 and CALR gene mutations with high
resolution melting (HRM)
The primers used for JAK2 and CALR were as follows. JAK2: forward,
5′-GGGTTTCCTCAGAACGTTGA-3′; reverse, 5′-CTGACACCTAGCTGTGA
TCCTG-3′, and CALR forward: 5′-TAACAAAGGTGAGGCCTGGT-3′; reverse,
5′-GGGACATCTTCCTCCTCATCT -3′. A LightCycler 480 (Roche) was used
for HRM and real-time thermal cycling. The reactions were per-
formed in 20 μL reaction volumes containing AmpliTaq Gold 360
Master Mix (Applied Biosystems) and GC enhancer HRM ResoLight
dye. The reaction conditions for real-time PCRwere as follows: 45 cy-
cles of thermal denaturation at 95 °C for 15 s, annealing at 58 °C for
30 s, and extension at 72 °C for 30 s. The reaction conditions for
HRM were 95 °C for 60 s and 40 °C for 60 s, which were determined
from the ﬂuorescence intensity of themelting curves by lowering the
temperature. Analysis was performed using LightCycler 480 and the
temperature shifts for JAK2 were 80.5–81 °C and 90–90.5 °C, for the
low and high temperature ranges, respectively, while those for
CALR were 73–73.5 °C and 79.5–80 °C, respectively. An additional
HRM analysis for the CALR mutation was performed according to a
protocol previously described [12].2.5. Statistical analysis
Mann-Whitney's U Test was used to determine statistical signiﬁ-
cance, with P values b0.05 regarded as signiﬁcant.3. Results
3.1. Mutation analysis of JAK2 by melting curve analysis and the CALR gene
by microchip electrophoresis and direct sequencing
We initially focused on 99 cases diagnosed as MPN and investi-
gated the JAK2 mutation using melting curve analysis. Representa-
tive melting curves are shown in Fig. 1. A peak of wave form was
observed in concordance with that of negative control in cases with
the wild-type JAK2 (Fig. 1a). In those with a heterozygous or homo-
zygous JAK2 mutation, a peak of wave form was shifted (Fig. 1b, c).
The ﬁnal diagnosis for these cases was PV in 38, ET in 43, PMF in 7,
and CML in 11. As shown in Table 1, the JAK2 mutation was detected
in 32 of the 38 PV cases (84%), 24 of the 43 ET cases (56%), and 4 of
the 7 PMF cases (57%) (See Supplementary Table S1 for detailed infor-
mation). Therefore, 61% (60/99 cases) of the present MPN patients
had the JAK2 mutation. Next, the CALR gene mutation was analyzed
using a microchip electrophoresis technique. A single band was ob-
served in cases with the wild-type CALR gene in exon 9 (Fig. 1d,
arrow). In those with a 52-bp deletion in exon 9, a band smaller than
that of the wild type was detected (Fig. 1e). Similarly, in cases with a
5-bp insertion, an additional band was detected (Fig. 1f). All cases
with the CALR genemutationwere conﬁrmed by ﬁndings of sequencing
analysis. As a result, 14 cases were positive for the CALRmutation. That
mutation was observed only in ET cases and not detected in cases pos-
itive for JAK2 (0/60 cases). Among 39MPN cases without the JAK2 mu-
tation, 14 (36%) were positive for the CALR mutation and 74% of all ET
cases without the JAK2 mutation were positive for the CALR mutation.
None of our cases were found to have an MPL mutation. Consequently,
among 43 ET cases, 38 (88%) possessed either the JAK2 or CALR muta-
tion. In accordancewith previous reports, JAK2 and CALRmutations ob-
served in MPN patients were mutually exclusive and most instances of
the CALRmutationwere observed as a 52-bp deletion (type 1) or a 5-bp
insertion (type 2). In the present cohort, 7 patients were deletion type
and 7 were insertion type.
170 N. Matsumoto et al. / Clinica Chimica Acta 462 (2016) 166–1733.2. Clinical characteristics of ET cases with or without CALR mutation
Previous studies have found that ET patientswith the CALRmutation
were older, had a lower hemoglobin (Hb) level and white blood cell
(WBC) count, and higher platelet (PLT) count and serum erythropoietin
level as compared to thosewith the JAK2mutation. In the present study,
we investigatedWBC count, Hb level, PLT count, mean corpuscular vol-
ume (MCV), mean platelet volume (MPV), and lactate dehydrogenase
(LD) level in ET patients, and compared between those with and with-
out the CALR and JAK2 mutations (Fig. 2). PLT count in patients
possessing the CALR mutation was signiﬁcantly higher as compared to
JAK2 mutation-positive patients (Fig. 2c). LD level showed a tendency
to be higher andMPV a tendency to be lower in patients with CALRmu-
tation than in those with the JAK2 mutation, though the differences
were not statistically signiﬁcant (Fig. 2d, f). WBC count, Hb level, and
MCV were not signiﬁcantly different between these groups (Fig. 2a–e).
3.3. Construction of simultaneous HRM test for determining JAK2 and CALR
mutations
Next, we constructed a screening test for simultaneous determina-
tion of the JAK2 and CALR gene mutations by utilizing high resolution
melting (HRM). Representative HRM curves are shown in Fig. 3a and
b (upper column). All 177 cases (including the above 99 cases)
suspected to be MPN and subjected to JAK2 mutation analysis in ourMutation
Wild
Hetero
Homo
n=177
JAK2(a)
Fig. 3. Results of simultaneous screening test for JAK2 and CALR mutations in 177 cases. (a,
mutations. (b, upper) Representative HRM curves of wild-type CALR, and low and high peak
mutations. (c,d, upper) The cluster of wild-type JAK2 and CALR. * a mutated sample add
heterozygous and homozygous JAK2 mutation. (d, middle and lower column) The cluster of delaboratory were analyzed using our novel test method (Fig. 3a and b,
lower column). As a result, the cluster of wild-type cases has been clear-
ly separated as shown in Fig. 3c and d (upper column). Similarly, in
cases with heterozygous JAK2 mutation, an evident cluster was ob-
served (Fig. 3c middle). However, in cases with homozygous JAK2 mu-
tation, the cluster was not clear and some curves looks like that of wild-
type (Fig. 3c lower column). Cases possessing mutated CALR showed
rounded curves (deletion) and lopsided shaped curves (insertion)
(Fig. 3d middle and lower column). After performing the simultaneous
screening test for the JAK2 and CALR gene mutations with HRM, we
compared the results to those obtained with conventional methods
(melting curve analysis for JAK2, microchip electrophoresis for CALR)
(Table. S1). The rate of concordance of conventional analysis ﬁndings
with those obtained with our HRMmethod was 89% for the JAK2muta-
tion and 95% for the CALR mutation.
3.4. Additional validation of screening for JAK2 usingHRMand another pro-
tocol for CALR using HRM
In the ﬁrst screening step, 14 cases that showed positive for the JAK2
mutation by the conventional method were negative with our HRM
method, suggesting a false negative result in each of those. Therefore,
we added a wild-type spike technique to our HRM method for deter-
mining the presence of the JAK2 mutation [13]. Using mixture samples
containing 40% wild-type DNA, 12 of those 14 cases successfullyMutation
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Insertion
(high peak)
Insertion
(low peak)
Deletion
CALR
n=177
(b)
upper) Representative HRM curves of wild-type JAK2, homozygous, and heterozygous
s of insertion and deletion type. (a,b, lower) Summarized HRM data for JAK2 and CALR
ed in order to show the whole picture. (c, middle and lower column) The cluster of
letion and insertion types of CALR mutation.
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JAK2 CALR(c) (d)
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Fig. 3 (continued).
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criminate between specimens with the wild-type and those with the
mutation (Fig. 4a, b). Although addition of JAK2 mixture samples for
HRM was required in this setting, the rate of concordance was im-
proved. As a result, the concordance rate of conventional analysis with
our HRM method for the JAK2 mutation rose to 96% (Table 2).
In addition, we investigated another HRM protocol for determining
the CALR mutation, as a recent report suggested that HRM for that mu-
tation was useful and showed a good concordance rate with a conven-
tional technique [12]. To evaluate this method in a simultaneous test
setting, we examined 14 CALR mutation cases (7 insertion type, 7 dele-
tion type) and 20 non-mutated cases. However, the concordance rate
for the CALR mutation in the present cases with use of this method
was only 64% (data not shown).4. Discussion
In the present study, we determined the presence of the CALR gene
mutation usingmicrochip electrophoresis and direct sequencing results
in 177 patientswhowere previously investigated for thepresence of the
JAK2 mutation as differential diagnosis of MPN at Nagasaki University
Hospital. All of the CALR mutation-positive cases were observed in ET
cases, and the CALR mutational frequency in JAK2/MPL-negative ET
cases was 74%. Among 43 ET cases, 38 (88%) possessed either the JAK2
or CALR mutation. Klampﬂ, et al. reported that CALR mutational fre-
quencies were detected in 67% and 88% of JAK2/MPL-negative ET and
PMF cases, respectively. Similarly, Nangalia, et al. found the CALRmuta-
tion in 71% of patients with ET and 56% of those with PMF. Although our
cohort included a small number of PMF cases, the present results in our
Wild
Mutation
False negative, n=14
Mutation
(a) (b)
Fig. 4. Additional validation of screening for JAK2 using HRM (a) JAK2 HRM curves of 14 cases shown positive for the JAK2 mutation by the conventional method and negative with our
HRMmethod. These cases possessed homozygous JAK2mutations, making them difﬁcult to analyze using HRM. (b)Wild-type spike technique for HRMmethod to determine presence of
the JAK2 mutation. Of the 14 false-negative cases in Fig. 4a, higher peaks were successfully displayed in 12 using the wild-type spike technique, allowing for discrimination between the
specimens possessing the wild-type and the mutation.
172 N. Matsumoto et al. / Clinica Chimica Acta 462 (2016) 166–173ET patients were in accordance with previous reports and indicate that
the frequency of the CALRmutation in Japan is similar to that inwestern
populations. Considering the promising results previously reported as
well as our present ﬁndings, we concluded that determination of the
CALR mutation is very useful for diagnosis of MPN and indicate the
need for revision of the diagnostic criteria in the near future.
Previous reports have found that ET patientswith CALRmutation are
older, have a lower Hb level and WBC count, and higher PLT count and
serum level of erythropoietin as compared to thosewith the JAK2muta-
tion. Our results also showed that the PLT count in cases with the CALR
mutation was signiﬁcantly higher as compared to JAK2 mutation-posi-
tive cases. In addition, LD level showed a tendency to be higher in our
cases with the CALR mutation as compared to those possessing the
JAK2 mutation. These results may suggest that cells with the CALR mu-
tation have different proliferative mechanisms as compared to those
possessing the JAK2 mutation.
Although the signiﬁcance and function of the CALR gene mutation
have not fully investigated, Klampf, et al. presented interesting experi-
mental results. They constructed cells expressing a type 1 CALR muta-
tion (52-bp deletion) using the interleukin-3 (IL-3)-dependent
murine cell line Ba/F3, which shows growth independent of IL-3 as
well as hypersensitivity to IL-3. To investigate whether IL-3 indepen-
dence in the CALR type 1-mutated cells was caused by activation of
JAK-signal transducer and activator of transcription (JAK-STAT) signal-
ing, they investigated their sensitivity to SAR302503, a JAK2 kinaseTable 2
Rate of concordance of conventional analysis with present HRMmethod.
JAK2 mutation CALR mutation
Melting curve
analysis
Microchip
electrophoresis
Positive Negative Positive Negative
HRM Positive 60 6 14 0
Negative 2 109 9 154
Match 169 168
Mismatch 8 9
Concordance ratio (%) 96 95
HRM: High resolution melting.inhibitor. Cells expressing non-mutated CALR or the type 1 CALRmuta-
tion showed sensitivity to SAR302503, suggesting that IL-3-indepen-
dent growth of cells possessing mutated CALR is depend on JAK2 or a
JAK family kinase targeted by SAR302503. Their results suggest that
the CALR mutation has a relationship with tumor growth activity, in
part due to the JAK-STAT signaling pathway.
For the present study, we constructed a novel test for simultaneous
screening of the JAK2 and CALR gene mutations by utilizing HRM, as a
recent study showed the possibility of usingHRM for CALR and reported
good rates of concordance with conventional methods [12]. Based on
these results, we modiﬁed the protocol for testing CALR with HRM. Un-
fortunately, the results were not adequate, as the concordance rate in
our experiment was only 64%, though we are not able to explain why
the results did not fully match. As for our method for using HRM to de-
termine possession of the JAK2mutation, we added a single spike tech-
nique in order to avoid false negative ﬁndings, which may have been
caused at least in part by automated protocol used by the LightCycler
480 device. When samples have homozygous JAK2 mutations, the
waveform peak shows a low curve, making it difﬁcult to distinguish
the wild from the mutant-type. Among the various mixing patterns ob-
served with samples possessing wild-type DNA, mixture samples con-
taining 40% of the wild-type were superior for discrimination between
wild and mutation-type samples. Although addition of JAK2 mixture
samples is required in this setting and there is room for further im-
provement, this techniquewas also effective against the unknown sam-
ples in our observation. As a result, the concordance rate of the
conventional method and our simultaneous HRM method for the JAK2
mutation was 96% and that for CALR mutation was 95%, which we con-
sider to be adequate for a screening test.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2016.09.023.
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